Literature DB >> 15004683

[Clinical research in the "acute and chronic leukemias"competence network ].

R Hehlmann1, U Berger, C Aul, T Büchner, H Döhner, G Ehninger, A Ganser, D Hoelzer, N Gökbuget, K Uberla.   

Abstract

Goal of the network is the construction of an exemplary cooperative leukemia network for the improvement of medical care and of health related research in acute and chronic leukemias. This is achieved by improved mechanisms of cooperation among all major groups in Germany that deal with the leukemias in research and in patient care. In practice, cooperation between clinical groups and scientists in research institutes is mediated by various instruments that improve communication, flow of information and interdisciplinary cooperation and also increase information transfer from top research institutions to clinical translation. The network comprises more than 1400 participants in about 400 university centers, large community hospitals and specialty practices with functional communication structures, interdisciplinary cooperation and nation-wide logistics. The improved cooperation and the accelerated information transfer from the bench to the "bedside" results in an added value that ultimately results in improved survival results of patients and in superior competitiveness of involved research workers and clinicians. Sustainability is addressed by establishing a leukemia foundation to support long term financial coverage of the network and by negotiating a proposal for a European Network of Excellence against leukemia within the Sixth Framework Programme of the European Union.

Entities:  

Mesh:

Year:  2004        PMID: 15004683     DOI: 10.1007/s00108-004-1151-5

Source DB:  PubMed          Journal:  Internist (Berl)        ISSN: 0020-9554            Impact factor:   0.743


  10 in total

1.  [Significance of networking for clinical research in the future].

Authors:  R Hehlmann
Journal:  Onkologie       Date:  2001-08

Review 2.  The ninth annual David Karnofsky Lecture. Treatment of acute lymphocytic leukemia.

Authors:  D Pinkel
Journal:  Cancer       Date:  1979-03       Impact factor: 6.860

3.  Letter: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining.

Authors:  J D Rowley
Journal:  Nature       Date:  1973-06-01       Impact factor: 49.962

4.  Outcome of adult patients with T-lymphoblastic lymphoma treated according to protocols for acute lymphoblastic leukemia.

Authors:  Dieter Hoelzer; Nicola Gökbuget; Werner Digel; Thomas Faak; Michael Kneba; Regina Reutzel; Joanna Romejko-Jarosinska; Jacek Zwolinski; Jan Walewski
Journal:  Blood       Date:  2002-06-15       Impact factor: 22.113

Review 5.  All-trans-retinoic acid as a differentiating agent in the treatment of acute promyelocytic leukemia.

Authors:  L Degos; H Dombret; C Chomienne; M T Daniel; J M Micléa; C Chastang; S Castaigne; P Fenaux
Journal:  Blood       Date:  1995-05-15       Impact factor: 22.113

6.  Double induction strategy for acute myeloid leukemia: the effect of high-dose cytarabine with mitoxantrone instead of standard-dose cytarabine with daunorubicin and 6-thioguanine: a randomized trial by the German AML Cooperative Group.

Authors:  T Büchner; W Hiddemann; B Wörmann; H Löffler; W Gassmann; T Haferlach; C Fonatsch; D Haase; C Schoch; D Hossfeld; E Lengfelder; C Aul; A Heyll; G Maschmeyer; W D Ludwig; M C Sauerland; A Heinecke
Journal:  Blood       Date:  1999-06-15       Impact factor: 22.113

7.  Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia.

Authors:  B J Druker; M Talpaz; D J Resta; B Peng; E Buchdunger; J M Ford; N B Lydon; H Kantarjian; R Capdeville; S Ohno-Jones; C L Sawyers
Journal:  N Engl J Med       Date:  2001-04-05       Impact factor: 91.245

8.  Growth of human normal and leukemic T cells: T-cell growth factor (TCGF) and the isolation of a new class of RNA tumor viruses (HTLV).

Authors:  R C Gallo
Journal:  Blood Cells       Date:  1981

9.  Randomized comparison of interferon alpha and hydroxyurea with hydroxyurea monotherapy in chronic myeloid leukemia (CML-study II): prolongation of survival by the combination of interferon alpha and hydroxyurea.

Authors:  R Hehlmann; U Berger; M Pfirrmann; A Hochhaus; G Metzgeroth; O Maywald; J Hasford; A Reiter; D K Hossfeld; H-J Kolb; H Löffler; H Pralle; W Queisser; M Griesshammer; C Nerl; R Kuse; A Tobler; H Eimermacher; A Tichelli; C Aul; M Wilhelm; J T Fischer; M Perker; C Scheid; M Schenk; J Weiss; C R Meier; S Kremers; L Labedzki; T Schmeiser; H-P Lohrmann; H Heimpel
Journal:  Leukemia       Date:  2003-08       Impact factor: 11.528

10.  Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype.

Authors:  C D Bloomfield; D Lawrence; J C Byrd; A Carroll; M J Pettenati; R Tantravahi; S R Patil; F R Davey; D T Berg; C A Schiffer; D C Arthur; R J Mayer
Journal:  Cancer Res       Date:  1998-09-15       Impact factor: 12.701

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.